SJ

Satish Jindal

General Partner, Advent Life Sciences, US, LLP

Cambridge, Massachusetts

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $25,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,000,000.00

Skills

Fundraising
Life Sciences
Biotechnology
Pharmaceutical Industry
Drug Discovery
Drug Development
Technology Transfer
Clinical Development
Oncology
Biopharmaceuticals
R&D
Biochemistry

Education

Lists including Satish

AP
AO
AS
AN

Based in UK

1884 people

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Amphista Therapeutics

Series A

Total Funding: $61M

Work Experience

Advent Life Sciences

2022

  • General Partner

    2022

    Through partnership with BioMotiv

Antolrx Pharmaceuticals

2014 - 2022

  • Board Member and Co-founder

    2014 - 2022

BioMotiv

2019 - 2021

  • CEO

    2019 - 2021

Elicio Therapeutics

2010 - 2019

  • Co-Founder/Founding CEO

    2010 - 2019

Allied-Bristol Life Sciences

2014 - 2019

  • CEO

    2014 - 2019

Bristol-Myers Squibb

2011 - 2014

  • Vice President, BMS;

    2011 - 2014

Verastem, Inc ( VSTM)

2009 - 2011

  • President/COO; Co-founder

    2009 - 2011

Schering-Plough Research Institute (now Merck)

2005 - 2008

  • VP and Site Head

    2005 - 2008

NeoGenesis Pharmaceuticals (acquired by Schering Plough)

1997 - 2005

  • CEO, Founder, Chairman, BoD

    1997 - 2005

PerSeptive Biosystems, Inc.

1995 - 1996

  • Senior Director

    1995 - 1996